BCL2 and neoplasm: Compared with nano-formulations for delivery DOX or siRNA alone, siRNA/DOX/GH-DPP nanoparticles showed stronger anti-tumor effect, indicating combination therapy could improve the anti-tumor efficiency by enhancing the sensitivity of cancer cells for chemotherapy drugs through inhibiting the expression of Bcl-2 protein (Chen et al., 2014).